Casio places Moflin AI companions in a Tokyo hospital's pediatric ward
Casio announced on April 9, 2026 that Moflin companions had been placed in the pediatric ward at The Jikei University Hospital in Tokyo starting February 9, 2026.
Full assessment3 claims · 4 technical notes · 2 sources
The pilot puts the AI companion with children in protective isolation rooms as a complement to medical staff.
WatchingWhether Casio publishes outcomes or extends the pilot to other hospitals.
The deployment documents one hospital pilot, not a published therapeutic program with measured results.
On autonomy
- Hospital placement uses the same commercial hardware; no new sensing or behavior was disclosed.
- Classification is unaffected by the deployment context; Moflin remains a Level I device.
On readiness
- Deployment extends Moflin into an institutional, non-retail setting for the first documented time.
- Casio describes the placement as a pilot with one hospital, not a general offering.
3 maker claims checked against the record. Open one to read the finding.
Casio frames the placement as the first use of Moflin in a pediatric hospital setting
Positioned as easing daily anxiety and stress for children in protective isolation
Presented as extending Moflin's role beyond its consumer retail use
2 sources · all linked
- 1Casio Newsroom (Global)9 Apr 2026
- 2Casio Press Release (PR Times, Japan)5 Feb 2026
Technical notes
4 sections
Deployment Details
Casio announced on April 9, 2026 that it had begun providing Moflin AI companions to the pediatric ward at The Jikei University Hospital in Tokyo, in cooperation with the hospital’s Department of Pediatrics. The placement started February 9, 2026, according to Casio’s Japanese-language release published in February.
Setting
The companions were placed with children in protective isolation rooms, used for treatments such as bone marrow transplantation, where infection-control measures restrict contact with people and objects. Casio describes the placement as intended to ease daily anxiety and stress for these patients.
Scope
Casio describes this as the first documented use of Moflin in a pediatric hospital setting. The release describes a cooperative pilot with a single hospital department rather than a broader institutional program, and no unit count for the placement was disclosed.
Product Continuity
The hospital units use the same commercial hardware and personality-development behavior as the retail product sold in Japan, the US, and the UK; no clinical-specific hardware or software variant was described.